JAGUAR HEALTH Aktie :: News | Aktienkurs | US47010C8881 | A414BN | FRA:1JA0

>JAGUAR HEALTH Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>JAGUAR HEALTH Aktie

Name:

JAGUAR HEALTH 25 DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US47010C8881 / A414BN

Symbol/ Ticker:

1JA0 (Frankfurt) / JAGX (NASDAQ)

Kürzel:

FRA:1JA0, ETR:1JA0, 1JA0:GR, NASDAQ:JAGX

Index:

Webseite:

https://jaguar.health/

Profil:

Marktkapitalisierung:

4.37 Mio. EUR

Unternehmenswert:

30 Mio. EUR

Umsatz:

10.21 Mio. EUR

EBITDA:

-26.48 Mio. EUR

Nettogewinn:

-34.91 Mio. EUR

Gewinn je Aktie:

-29.44 EUR

Schulden:

27.64 Mio. EUR

Liquide Mittel:

3.06 Mio. EUR

Operativer Cashflow:

-22.54 Mio. EUR

Bargeldquote:

0.1

Umsatzwachstum:

12.45%

Gewinnwachstum:

-6.76%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

JAGUAR HEALTH

Letzte Datenerhebung:

07.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 3.74 Mio. St.

Frei handelbar: 59.04%

Leerverk. Aktien: 3.5%

Rückkaufquote: -278.01%

Mitarbeiter: 49

Umsatz/Mitarb.: 0.21 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 1775%

Bewertung:

KGV: -

KGV lG: -

KUV: 0.05

KBV: 0.47

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 62.78%

Gewinnmarge: -341.9%

Operative Marge: -278.52%

Managementeffizenz:

Gesamtkaprendite: -74.66%

Eigenkaprendite: -370.95%

>Peer Group

Gesundheit

07.04.26 - 14:42	Jaguar Health, Inc.: Jaguar Health Reports 2025 Financials (Accesswire)
	Net revenue increase of 5% in Q4 2025 vs. Q3 2025Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi a......

02.04.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress (Accesswire)
	Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MV......

16.03.26 - 14:06	Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression (Accesswire)
	Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX)......

13.03.26 - 01:25	Jaguar Health: Strategische Neuausrichtung auf seltene Krankheiten (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.03.26 - 14:06	Jaguar Health, Inc.: Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts (Accesswire)
	SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursda......

09.03.26 - 14:09	Jaguar Health, Inc.: Jaguar Health Strengthens Company′s Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants (Accesswire)
	Strengthening balance sheet and capitalization is a key Jaguar priorityCompany continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure ......

03.03.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 (Accesswire)
	As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's two co......

02.03.26 - 15:03	Jaguar Health, Inc.: Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health′s Special One-time Stock Dividend (Accesswire)
	Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, ......

18.02.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Announces a Special One-time Stock Dividend (Accesswire)
	Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 / Jaguar Health, Inc.......

22.01.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi (Accesswire)
	Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi and Canalevia-CA1, which has the potential to provide Jaguar up to an add......

14.01.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts (Accesswire)
	SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thurs......

12.01.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million (Accesswire)
	$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)Up to additional $20M in milestone and other future paymentsFuture Pak becomes exclusive U.......

06.01.26 - 15:06	Jaguar Health, Inc.: Article About Groundbreaking Results from Study of Jaguar Health′s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication (Accesswire)
	Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssocia......

02.01.26 - 15:06	Jaguar Health, Inc.: Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs (Accesswire)
	SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Cen......

15.12.25 - 15:06	Jaguar Health, Inc.: Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (Accesswire)
	SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in Oct......

08.12.25 - 22:30	Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders (Accesswire)
	Jaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerInitial results of ongoi......

24.11.25 - 18:42	Patent in Australien für Crofelemer treibt Aktie von Jaguar Health an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

24.11.25 - 15:06	Jaguar Health, Inc.: Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones (Accesswire)
	This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelem......

20.11.25 - 15:06	Jaguar Health, Inc.: In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease, Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial (Accesswire)
	Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the diseaseParenteral support reduction of up to 37% is groundbreaking; No app......

17.11.25 - 16:21	Jaguar Health outlines dual NDA filing targets for late 2026 as clinical catalysts converge (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...